Questions?

Request a Medical Science Liaison (MSL)

Questions?

Request a Medical Science Liaison (MSL)

UPTRAVI Delays Disease Progression1

Time to first PAH disease progression event1,2
Percent of patients without an event on UPTRAVI vs placebo desktop curve
Percent of patients without an event on UPTRAVI vs placebo desktop curve
Percent of patients without an event on UPTRAVI vs placebo desktop curve
Study Design

Proven in a Broad Range of Patients1

GRIPHON is the largest adult PAH pivotal trial, studied as monotherapy, dual therapy (ERA or PDE5i), and triple therapy (ERA + PDE5i)1,2

GRIPHON: Multicenter, long-term, double-blind, placebo-controlled, parallel-group, event-driven, phase 3 trial1,3

1156 Adult Patients

UPTRAVI (selexipag):
n=574

Placebo: n=582

Mean age:
48 years

Female:
80%

1.4 Years (duration of exposure to UPTRAVI)

Longest endpoint evaluation period of any prostacyclin pathway therapy

0.9 Years 

Median time from PAH diagnosis in patients taking UPTRAVI

New England Journal of Medicine Clinical Trial Publication for GRIPHON

Download

This article includes information that has not been approved by the Food and Drug Administration for UPTRAVI. Please see full Prescribing Information available on this website. Authors[s] of this article have received remuneration from Actelion Pharmaceuticals US, Inc., or its affiliates.

†Other=drugs and toxins (2%) and HIV (1%).
ERA=endothelin receptor antagonist; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; HIV=human immunodeficiency virus; HPAH=heritable PAH; IPAH=idiopathic PAH; PAH=pulmonary arterial hypertension; PAH-CHD=PAH associated with congenital heart disease with repaired shunts; PAH-CTD=PAH associated with connective tissue disease; PDE5i=phosphodiesterase type 5 inhibitor.
References: 1. UPTRAVI (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Data on file. Actelion Pharmaceuticals US, Inc. Length and Population Size of PAH Pivotal Trials Confirmation. June 2024. 3. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522-2533. 4. Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801908. doi:10.1183/13993003.01908-2018 5. Data on file. Actelion Pharmaceuticals US, Inc. GRIPHON Baseline Characteristics Study Report.

Proven in a Broad Range of Patients1

GRIPHON is the largest adult PAH pivotal trial, studied as monotherapy, dual therapy (ERA or PDE5i), and triple therapy (ERA + PDE5i)1,2

GRIPHON: Multicenter, long-term, double-blind, placebo-controlled, parallel-group, event-driven, phase 3 trial1,3

1156 Adult Patients

UPTRAVI (selexipag):
n=574

Placebo: n=582

Mean age:
48 years

Female:
80%

1.4 Years (duration of exposure
to UPTRAVI)

Longest endpoint evaluation period of any prostacyclin pathway therapy

0.9 Years 

Median time from PAH diagnosis in patients taking UPTRAVI

New England Journal of Medicine Clinical Trial Publication for GRIPHON

Download

This article includes information that has not been approved by the Food and Drug Administration for UPTRAVI. Please see full Prescribing Information available on this website. Authors[s] of this article have received remuneration from Actelion Pharmaceuticals US, Inc., or its affiliates.

†Other=drugs and toxins (2%) and HIV (1%).
ERA=endothelin receptor antagonist; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; HIV=human immunodeficiency virus; HPAH=heritable PAH; IPAH=idiopathic PAH; PAH=pulmonary arterial hypertension; PAH-CHD=PAH associated with congenital heart disease with repaired shunts; PAH-CTD=PAH associated with connective tissue disease; PDE5i=phosphodiesterase type 5 inhibitor.
References: 1. UPTRAVI (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Data on file. Actelion Pharmaceuticals US, Inc. Length and Population Size of PAH Pivotal Trials Confirmation. June 2024. 3. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522-2533. 4. Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801908.
doi:10.1183/13993003.01908-2018 5. Data on file. Actelion Pharmaceuticals US, Inc. GRIPHON Baseline Characteristics Study Report.

Summary of primary endpoint events1

UPTRAVI n=574
% (n)		Placebo n=582
% (n)
All primary endpoint events27.0% (155)41.6% (242)
FIRST EVENT WAS
Hospitalization for PAH		13.6% 
(78)		18.7% (109)
Other disease progression
(decrease in 6MWD plus worsening FC or need for other therapy)		6.6% 
(38)		17.2% (100)
Death4.9% (28)3.1% (18)
Parenteral prostanoid or chronic oxygen therapy1.7% (10)2.2% (13)
Need for lung transplantation or balloon atrial septostomy for worsening of PAH0.2% (1)0.3% (2)
UPTRAVI (selexipag) is the only prostacyclin pathway therapy indicated to delay disease progression AND reduce risk of PAH-related hospitalization1,3

VIEW hospitalization DATA

*Hazard ratio based on primary endpoint events up to the end of treatment.

6MWD=6-minute walk distance; CI=confidence interval; ERA=endothelin receptor antagonist; FC=Functional Class; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensION; HR=hazard ratio; PAH=pulmonary arterial hypertension; PDE5i=phosphodiesterase type-5 inhibitor.

References: 1. UPTRAVI (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522-2533. 3. Data on file. Actelion Pharmaceuticals US, Inc. UPTRAVI Indication Confirmation.